Search bioRxiv⌕ Search

Biology subjects

Havlicek, V.

Publications and source records attributed to Havlicek, V..

2 recordsLinked to original sources

Multimodal Imaging Reveals Spatial Host-Pathogen Microenvironments in Escherichia coli Meningoencephalitis

Experimental bacterial meningitis is often analyzed as microbial burden and inflammation, but the tissue-level organization of host-pathogen interplay remains poorly resolved. Here, we use multimodal imaging to map Escherichia coli meningoencephalitis as a spatially organized process across infected rat brain tissue and cerebrospinal fluid (CSF). A low-dose intracerebral inoculum expands within 24 h into an anatomically structured infection involving ventricular, meningeal, and perivascular interfaces. Scanning electron microscopy reveals biofilm-like multicellular E. coli aggregates embedded in extracellular material, consistent with neutrophil extracellular traps. MALDI mass spectrometry imaging detects aerobactin and salmochelin-derived metabolites, whereas intact enterobactin is not detected despite favorable analytical sensitivity. These bacterial iron-acquisition signals partially overlap with calprotectin proteoforms, defining ventricular and periventricular metal-conflict microenvironments. Spatial peptidomics identifies infection-enriched antimicrobial territories dominated by rat neutrophil peptides RatNP-2, RatNP-3, and RatNP-4. Endogenous proenkephalin-derived neuropeptides are reduced in basal ganglia regions. Finally, cerebrospinal fluid captures both bacterial siderophores and host antimicrobial peptides with lipocalin-2 protein, linking tissue-resolved host-pathogen chemistry to a proximal diagnostic fluid. Together, these data show that experimental E. coli meningoencephalitis is a spatially organized host-pathogen process. Bacterial communities, nutritional immunity, antimicrobial peptides, and neuropeptide networks occupy distinct but connected CNS niches, components of which are recoverable in CSF.

neuroscience↗

Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb and reverses HIV-1 latency

A leading pharmacological strategy towards HIV cure requires "shock" or activation of HIV gene expression in latently infected cells with Latency Reversal Agents (LRAs) followed by their subsequent clearance. In a screen for novel LRAs we used fungal secondary metabolites (extrolites) as a source of bio-active molecules. Using orthogonal mass spectrometry (MS) coupled to latency reversal bioassays, we identified gliotoxin (GTX) as a novel LRA. GTX significantly induced HIV-1 gene expression in latent ex vivo infected primary cells and in CD4+ T cells from all aviremic HIV-1+ participants. RNA sequencing identified 7SK RNA, the scaffold of the P-TEFb inhibitory 7SK snRNP complex to be significantly reduced upon GTX treatment of independent donor CD4+T cells. GTX disrupted 7SK snRNP, releasing active P-TEFb, which then phosphorylated RNA Pol II CTD, inducing HIV transcription. Our data highlight the power of combining a medium throughput bioassay, mycology and orthogonal mass spectrometry to identify novel potentially therapeutic compounds.

molecular biology↗